Literature DB >> 9533457

Antibiotic-induced release of endotoxin: in-vitro comparison of meropenem and other antibiotics.

M Trautmann1, R Zick, T Rukavina, A S Cross, R Marre.   

Abstract

The influence of meropenem, a new carbapenem antibiotic, on cell morphology and in-vitro lipopolysaccharide (LPS) release from Escherichia coli was compared with that of imipenem, ceftazidime, tobramycin and ciprofloxacin. Free and cell-associated LPS was quantified by means of a capture ELISA method based on the recognition of E. coli LPS by monoclonal antibodies. Microscopically, meropenem was found to induce spheroplast formation similar to that seen with imipenem, while ceftazidime and ciprofloxacin induced filament formation. Free and cell-associated LPS levels were low in the presence of meropenem, imipenem, ciprofloxacin and tobramycin, but high in the presence of ceftazidime. Reduced endotoxin release appears to be a common property of carbapenem antibiotics. Morphological changes in bacteria in the presence of antibiotics do not predict their LPS-liberating effect since ciprofloxacin induced low levels of LPS despite causing filament formation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9533457     DOI: 10.1093/jac/41.2.163

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  12 in total

1.  Validation of a noninvasive, real-time imaging technology using bioluminescent Escherichia coli in the neutropenic mouse thigh model of infection.

Authors:  H L Rocchetta; C J Boylan; J W Foley; P W Iversen; D L LeTourneau; C L McMillian; P R Contag; D E Jenkins; T R Parr
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

Review 2.  Interference of antibacterial agents with phagocyte functions: immunomodulation or "immuno-fairy tales"?

Authors:  M T Labro
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

Review 3.  The front line of enteric host defense against unwelcome intrusion of harmful microorganisms: mucins, antimicrobial peptides, and microbiota.

Authors:  Vanessa Liévin-Le Moal; Alain L Servin
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

Review 4.  Meropenem: a review of its use in patients in intensive care.

Authors:  M Hurst; H M Lamb
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

5.  Effect of empiric antibiotic treatment on plasma endotoxin activity in septic patients.

Authors:  F Mignon; M Piagnerelli; M Van Nuffelen; J L Vincent
Journal:  Infection       Date:  2014-01-28       Impact factor: 3.553

Review 6.  Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis.

Authors:  Roland Nau; Helmut Eiffert
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

7.  Rifampin followed by ceftriaxone for experimental meningitis decreases lipoteichoic acid concentrations in cerebrospinal fluid and reduces neuronal damage in comparison to ceftriaxone alone.

Authors:  Joachim Gerber; Karin Pohl; Valeska Sander; Stephanie Bunkowski; Roland Nau
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

8.  The anti-Pseudomonas aeruginosa antibody Panobacumab is efficacious on acute pneumonia in neutropenic mice and has additive effects with meropenem.

Authors:  Thomas Secher; Stefanie Fas; Louis Fauconnier; Marieke Mathieu; Oliver Rutschi; Bernhard Ryffel; Michael Rudolf
Journal:  PLoS One       Date:  2013-09-02       Impact factor: 3.240

9.  Factors associated with marketable milk production recovery after treatment of naturally occurring acute coliform mastitis.

Authors:  Yasunori Shinozuka; Sohei Kaneko; Tomoyasu Kurose; Aiko Watanabe; Kana Kuruhara; Kazuhiro Kawai
Journal:  J Vet Med Sci       Date:  2016-02-09       Impact factor: 1.267

Review 10.  The multifaceted nature of antimicrobial peptides: current synthetic chemistry approaches and future directions.

Authors:  Bee Ha Gan; Josephine Gaynord; Sam M Rowe; Tomas Deingruber; David R Spring
Journal:  Chem Soc Rev       Date:  2021-07-05       Impact factor: 54.564

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.